Skip to main content
. 2020 Jun;16(2):200058. doi: 10.1183/20734735.0058-2020

Table 1.

Currently available biologics for T2 asthma

Drug Mechanism Route
Omalizumab Anti-IgE Subcutaneous
Mepolizumab Anti-IL-5 Subcutaneous
Reslizumab Anti-IL-5 Intravenous
Benralizumab Anti-IL-5Rα Subcutaneous
Dupilumab Anti-IL-4Rα Subcutaneous

R: receptor.